Qingdao Vland Biotech Co Ltd (SHG:603739) — Market Cap & Net Worth
Market Cap & Net Worth: Qingdao Vland Biotech Co Ltd (603739)
Qingdao Vland Biotech Co Ltd (SHG:603739) has a market capitalization of $562.80 Million (CN¥3.85 Billion) as of May 7, 2026. Listed on the SHG stock exchange, this China-based company holds position #11951 globally and #3672 in its home market, demonstrating a 2.70% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Qingdao Vland Biotech Co Ltd's stock price CN¥15.20 by its total outstanding shares 253028866 (253.03 Million). Analyse 603739 cash flow metrics to see how efficiently the company converts income to cash.
Qingdao Vland Biotech Co Ltd Market Cap History: 2019 to 2026
Qingdao Vland Biotech Co Ltd's market capitalization history from 2019 to 2026. Data shows change from $650.69 Million to $562.80 Million (-7.78% CAGR).
Qingdao Vland Biotech Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Qingdao Vland Biotech Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.34x
Qingdao Vland Biotech Co Ltd's market cap is 0.34 times its annual revenue
Latest Price to Earnings (P/E) Ratio
7.09x
Qingdao Vland Biotech Co Ltd's market cap is 7.09 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $650.69 Million | $846.78 Million | $77.75 Million | 0.77x | 8.37x |
| 2020 | $576.78 Million | $960.25 Million | $108.98 Million | 0.60x | 5.29x |
| 2021 | $676.21 Million | $1.15 Billion | $132.57 Million | 0.59x | 5.10x |
| 2022 | $493.13 Million | $1.16 Billion | $69.84 Million | 0.42x | 7.06x |
| 2023 | $563.54 Million | $1.20 Billion | $80.71 Million | 0.47x | 6.98x |
| 2024 | $443.94 Million | $1.32 Billion | $62.64 Million | 0.34x | 7.09x |
Competitor Companies of 603739 by Market Capitalization
Companies near Qingdao Vland Biotech Co Ltd in the global market cap rankings as of May 7, 2026.
Key companies related to Qingdao Vland Biotech Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $108.50 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #357 globally with a market cap of $74.92 Billion USD.
- UCB SA (BR:UCB): Ranked #513 globally with a market cap of $51.74 Billion USD ( €44.26 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #572 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $108.50 Billion | $427.65 |
| #357 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.92 Billion | $721.05 |
| #513 | UCB SA | BR:UCB | $51.74 Billion | €236.00 |
| #572 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Qingdao Vland Biotech Co Ltd Historical Marketcap From 2019 to 2026
Between 2019 and today, Qingdao Vland Biotech Co Ltd's market cap moved from $650.69 Million to $ 562.80 Million, with a yearly change of -7.78%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥562.80 Million | +7.42% |
| 2025 | CN¥523.92 Million | +18.02% |
| 2024 | CN¥443.94 Million | -21.22% |
| 2023 | CN¥563.54 Million | +14.28% |
| 2022 | CN¥493.13 Million | -27.07% |
| 2021 | CN¥676.21 Million | +17.24% |
| 2020 | CN¥576.78 Million | -11.36% |
| 2019 | CN¥650.69 Million | -- |
End of Day Market Cap According to Different Sources
On May 7th, 2026 the market cap of Qingdao Vland Biotech Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $562.80 Million USD |
| MoneyControl | $562.80 Million USD |
| MarketWatch | $562.80 Million USD |
| marketcap.company | $562.80 Million USD |
| Reuters | $562.80 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Qingdao Vland Biotech Co Ltd
Qingdao Vland Biotech INC. engages in the research and development, production, and sale of enzyme preparations, microecological preparations, and animal health products in China and internationally. It offers feed, industrial, and food enzymes; and probiotics, including aquaculture premixes, health products, and animal and plant probiotics. The company also offers animal vaccines and biological … Read more